Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Upgraded by Royal Bank Of Canada to Moderate Buy Rating

Royal Bank Of Canada upgraded shares of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) to a moderate buy rating in a research report report published on Thursday morning,Zacks.com reports.

Several other equities research analysts also recently commented on the stock. Zacks Research raised shares of Damora Therapeutics, Inc. Common Stock to a “hold” rating in a research note on Friday, January 9th. Guggenheim reissued a “buy” rating and issued a $40.00 target price (up from $36.00) on shares of Damora Therapeutics, Inc. Common Stock in a research report on Tuesday, February 17th. UBS Group assumed coverage on shares of Damora Therapeutics, Inc. Common Stock in a research report on Tuesday, February 17th. They set a “buy” rating and a $45.00 price target on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Damora Therapeutics, Inc. Common Stock in a report on Monday, December 29th. Finally, Leerink Partners started coverage on shares of Damora Therapeutics, Inc. Common Stock in a research note on Wednesday, January 7th. They issued an “outperform” rating and a $46.00 target price for the company. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $43.40.

Damora Therapeutics, Inc. Common Stock Stock Down 2.6%

NASDAQ:DMRA opened at $24.75 on Thursday. Damora Therapeutics, Inc. Common Stock has a 12-month low of $2.45 and a 12-month high of $38.33. The stock’s fifty day simple moving average is $27.04 and its 200-day simple moving average is $22.75. The firm has a market capitalization of $1.49 billion, a P/E ratio of -2.05 and a beta of 1.59.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Ikarian Capital LLC acquired a new position in Damora Therapeutics, Inc. Common Stock during the fourth quarter worth $6,574,000. Jain Global LLC bought a new position in Damora Therapeutics, Inc. Common Stock in the 4th quarter worth about $2,774,000. Remedium Capital Partners LLC bought a new position in shares of Damora Therapeutics, Inc. Common Stock in the fourth quarter valued at approximately $2,772,000. Boothbay Fund Management LLC bought a new stake in Damora Therapeutics, Inc. Common Stock during the fourth quarter valued at $2,204,000. Finally, Connective Capital Management LLC bought a new stake in Damora Therapeutics, Inc. Common Stock in the 3rd quarter worth approximately $100,000. 14.20% of the stock is owned by institutional investors and hedge funds.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto Inc is a clinical?stage biotechnology company developing small?molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin?3, an extracellular carbohydrate?binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase?like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin?3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin?3 inhibitor being evaluated for systemic fibrotic disorders.